Gene Delivery Using Chemical Methods - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 204

[379] Hosseinkhani H, Azzam T, Tabata Y, Domb AJ. Dextran-spermine polycation:
an efficient non-viral vector for in vitro and in vivo gene transfection. Gene Ther
2004;11:194-203.
[380] Truong-Le VL, Walsh SM, August JT, Leong KW. Gene transfer by gelatin-DNA coac-
ervate. Proc Inter Symp Control Rel Bioact Mater 1995;22:466-7.
[381] Truong-Le VL, August JT, Leong KW. Controlled gene delivery by DNA-gelatin nano-
spheres. Hum Gene Ther 1998;9:1709-17.
[382] Truong-Le VL, Walsh SM, Schweibert E, Mao HQ, Guggino WB, et al. Gene transfer
by DNA-gelatin nanospheres. Arch Biochem Biophys 1999;361:47-56.
[383] Kaul G, Amiji M. Biodistribution and targeting potential of poly(ethylene glycol)-
modified gelatin nanoparticles in subcutaneous murine tumor model. J Drug Target
2004;12:585-91.
[384] Kaul G, Amiji M. Tumor-targeted gene delivery using poly (ethylene glycol)-modified
gelatin nanoparticles: in vitro and in vivo studies. Pharm Res 2005;22:951-61.
[385] Konstan MW, Davis PB, Wagener JS, Hilliard KA, Stern RC, Milgram LH, et al.
Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis sub-
jects are safe and demonstrate partial to complete cystic fibrosis transmembrane regula-
tor reconstitution. Hum Gene Ther 2004;15:1255-69.
[386] Lori F, Trocio J, Bakare N, Kelly LM, Lisziewicz J. DermaVir, a novel HIV immunisa-
tion technology. Vaccine 2005;23:2030-4.
[387] Ohana P, Gofrit O, Ayesh S, Al-Sharef W, Mizrahi A, Birman T, et al. Regulatory
sequences of the H19 gene in DNA-based therapy of bladder cancer. Gene Ther Mol
Biol 2004;8:181-92.
[388] Heidel JD, Yu Z, Liu JYC, Rele SM, Liang Y, Zeidan RK, et al. Administration in
non-human primates of escalating intravenous doses of targeted nanoparticles con-
taining ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci USA
2007;104:5715-21.
[389] Porteous DJ, Dorin JR, McLachlan G, Davidson-Smith H, David H, Stevenson BJ,
et al. Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR
gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther 1997;
4:210-18.
[390] Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB, et al. Cationic lipo-
some-mediated E1A gene transfer to human breast and ovarian cancer cells and its bio-
logic effects: a phase I clinical trial. J Clin Oncol 2001;19:3422-33.
[391] Yoo GH, Hung M-C, Lopez-Berestein G, LaFollette S, Ensley JF, Carey M, et al. Phase
I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and
head and neck cancer. Clin Cancer Res 2001;7:1237-45.
[392] Villaret D, Glisson B, Kenady D, Hanna E, Carey M, Gleich L, et al. A multicenter
phase II study of tgDCC-E1A for the intratumoral treatment of patients with recurrent
head and neck squamous cell carcinoma. Head Neck 2002;24:661-9.
[393] Voges J, Reszka R, Gossmann A, Dittmar C, Richter R, Garlip G, et al. Imaging-
guided convection-enhanced delivery and gene therapy of glioblastoma. Ann Neurol
2003;54:479-87.
[394] Noone PG, Hohneker KW, Zhou Z, Johnson LG, Foy C, Gipson C, et al. Safety and
biological efficacy of lipid-CFTR complex for gene transfer in the nasal epithelium of
adult patients with cystic fibrosis. Mol Ther 2000;1:1156-65.
[395] Mackensen A, Veelken H, Lahn M, Wittnebel S, Becker D, Kohler G, et al. Induction of
tumor-specific cytotoxic T lymphocytes by immunization with autologous tumor cells
and interleukin-2 gene transfected fibroblasts. J Mol Med 1997;75:290-6.